Clinical logistics · the long middle
The second-year plateau: when the flat line is the finish line — and the honest checklist for when it isn’t
Year-two flat is a different animal from month-four flat. The trial curves say so: loss concentrates in the first 9–12 months, then trajectories flatten at the trough by design — continued therapy in the maintenance extensions mostly held weight rather than compounding it, which means a stable year-two scale is very often the medication succeeding at its second job. The honest sequence before touching anything: run the standard audit (adherence, behavior, headroom — step zero, always); then run the year-two additions — the goal re-audit (is the number you’re chasing this year’s goal or last year’s momentum?), the recomposition check (photos and waist catching what the scale hides when training entered the picture), and the maintenance-versus-stall verdict. If escalation is still warranted after all that, year-two levers run in order — ceiling confirmation, behavioral re-periodization, and the molecule switch-up with its caveat stated plainly: the head-to-head’s ~6-point gap was measured in treatment-naive populations, and switching after a deep first-year response is a smaller, less-charted bet your prescriber prices. And if the verdict is maintenance? Then the project changes names, and the money section below is the new syllabus.
Why year two flattens — the body’s side of the negotiation
Sustained loss recruits sustained resistance: energy expenditure adapts downward as mass leaves, appetite signaling pushes back, and the medication’s job quietly shifts from driving deficit to defending the new equilibrium against that push. The trial architecture mirrors it — the big programs’ curves decelerate through the back half of year one and run near-flat thereafter on continued therapy, while the withdrawal arms regained — which yields this page’s central reframe: at year two, a flat line on medication is the visible signature of an invisible fight being won. That doesn’t make every flat line maintenance (the audit exists because drift is real), but it flips the default: month-four flat asks “what’s wrong?”; month-twenty flat asks “is anything wrong at all?” — and answering that honestly is the section below.
Stall or maintenance — the three-part verdict
Part one, the standard audit — adherence, behavior, headroom — because year-two drift wears year-one costumes (stretched intervals, protein slippage) and the diary’s columns settle it in minutes. Part two, the goal re-audit: put last year’s target next to this year’s health markers — labs that normalized, function that returned, the 10–15%+ already banked where outcome dividends concentrate — and ask whether the remaining gap is medicine or aesthetics inertia; both are allowed, but they’re different projects with different risk budgets. Part three, the recomposition check: anyone who added resistance training mid-course can hold scale-flat while trading fat for lean — the photo protocol and a tape measure adjudicate what the bathroom scale constitutionally cannot. Three parts clean → the verdict is maintenance, congratulations are literal, and you skip to the money section. Any part dirty → the levers, in order.
The year-two levers — ordered by evidence and reversibility
Lever one, ceiling confirmation: plenty of second-year patients plateaued below maximum tolerated dose for historical reasons (a rough titration week that froze the ladder); confirming true headroom with your prescriber is the cheapest possible move. Lever two, behavioral re-periodization: the scaffold that drove year one — protein floor, training blocks, sleep — responds to novel structure more than renewed intention; a deliberate 8–12-week block with one variable actually changed outperforms vague re-commitment. Lever three, the molecule switch-up — semaglutide to tirzepatide via the standard bridge — carrying the year-two caveat in bold: the ~20-versus-14 trial gap comes from treatment-naive cohorts, and expecting the full delta on top of a deep existing response over-promises; prescribers frame it as a legitimate, smaller-expected-value experiment, and the diary re-baselines on switch day so twelve weeks later the experiment reports honestly. What never makes the lever list: stacking, boosters, and forum improvisation — year two changes the question, not the counterfeits.
The economics of holding — maintenance’s own optimization
A maintenance verdict converts the plateau from problem to budget line, and budget lines get optimized: run the annual review against the corrected field (year-two patients are exactly who grandfathered-drift and match letters were built for), re-check coverage at every enrollment (maintenance-era prior authorizations argue continuity with a year of receipts — the appeal anatomy applies), and mind the maintenance-specific trap: dose-tier programs bill their maximum exactly when you’ve settled at top dose forever — the structural argument for flat, dose-proof pricing that the maintenance board makes in detail, and the reason a both-molecule flat roof also keeps lever three a clinical decision rather than a billing event. Flat at maintenance — the audited structure ↗ If the year-two verdict someday becomes an exit experiment instead, the stopping-well file and the restart file are the bookends already written.
FAQ
Is it normal to stop losing weight in year two on GLP-1s?
Yes — trial trajectories flatten after the first 9–12 months, and continued therapy mostly holds the trough; a stable year-two weight is often maintenance succeeding, verified by the three-part verdict.
Should I switch to tirzepatide if semaglutide plateaued at year two?
It’s a legitimate prescriber-managed option with honest caveats: the trial gap was measured in treatment-naive patients, so expected additional loss after a deep response is smaller — re-baseline and judge at twelve weeks.
What should change financially at maintenance?
Run the annual review, use tenure in negotiations, argue continuity in coverage paperwork, and avoid dose-tier structures that bill maximum rates for the dose you’ll hold indefinitely.